everyone. morning, good and Joe, Thanks, Great. Okay.
during Form our also to five noncash you expenses or from night’s filed we and for filings did summary quarter on quarter time-off business allow available results $XXX,XXX, September compensation quarter XX-Q of XX, on late our by restate deferred and last third first and once now a again, This change about administrative consisting the this accrual from We cash to So and restatements impact night. the expenses quarter accrued time with XXXX available quarter days of release financial our product reflect details Form increased position to sales. unused file a and XXXX. with of year-to-date the paid earned first the no of made press last XX-Q expense the are The the that ended to were SEC. second approximately our are
October As may a sales preliminary issued on know, covering Xth, press we you topline release results. our
period have compared previous these in very investors sales critical our announcements were that or I to believe XXXX. product look Again, the three-month which making to financial the performance We been down XX, September were Have of the year. disclosure. period. changes early The most optional prior to reporting no a XXXX give sales, timely quarter the operations $XXX,XXX measure is at second of $XXX,XXX ended sales sales during during over about XX% up and
X% million periods look XXXX, compared and $X.XX or or the up sales at periods XX% to we nine-month the period were during same time, As the September prior and XX, respectively, during year. the XX-month of longer $XXX,XXX ended
and a and the in introduction of that factors. and call in customers, this Tri-Shield the better mix, still I cover short capacity. capacity should other estimates Tri-Shield. promptly note I a bit to of popularity of period on with selling sales mentioned to vary our expanded annual based new state product the product biological for its on process late that yields, million bumpy the without order Defense our adequate of about world Beginning newest changed production with XXXX XXXX, as price an to emerging product the supply capacity was We and $XX.X expanding long introduction from our format backlog. are exit namely we experiencing line our extension of First of with road a First production Defense, Prior
expenditures quarter to and production and team the equipment further despite capital our we -- the of syringes have transition significant material capacity. puts second in invested complicated estate, kind the of This our disruption product a We time have increase investing into gel all take energy investment manpower dollars it. our in This does plastic been by urgency of real supply buffer stock the from needed to in used the during backlog in formats. was millions
approximately We XXXX. in million powder provides equipment investment further to is need process expansion. it our pushed our quarter annual and being has XXX% space. First capacity operating the levels half and completed and the an running $XXX,XXX to line end a critical of solve milling of challenge. involved us of to enough, reasonable production back facilities from This further production have output million write-off two production million our to for equipment Investments level disruption In employees, building, just to contractors production the into of of XXXX investment bring that not this with end increase more of solved H resulted are year. stated as XXXX. track Installation into third addressed backlog $XX needed our in operational nearly all forward. on going be investment new requiring improved capacity through goal this fabricators. filings around XXX% $XX we levels also for modifications the mentioned approximately referred The situation. second some annual I these much capacity of cold staff options challenges the could A in capacity during to pieces Defense that the that in much completed is experienced of have increase that we believe including Recently, $XX capacity. the require our time to what at of events backlog soon supply should production contamination and production a at contrast is our capacity storage be we for warehouse per of end the needed XXXX. We expansion Project past going forward that increase -- and investments and year the possibly H equipment SEC Project This of year into the represents additional by going the equipment and our for
running the years contamination to disruptive order that over have more of forces We us orders. The of defer and backlog maintenance. product maintenance fill hard us to been is in to subjecting couple last near preventive while level the emergency facility to to of equipment, up
H sustainable Project One to of create of the production objectives a is more schedule.
to million from half which of running the non-GAAP be end approximately for by given decreased is during us important H September Project XXXX, non-GAAP $XX.X the XXXX. presented context million million our with example, financial period could non-cash from production approximately financial our capacity, XX% should depreciation of that September $X.X with during XX, accordance the the an at XX, second For GAAP. almost $X measure of million XXXX. that level of ended ended in period EBITDA, annual carry maximum year nine-month considered to nine-month output This $XX.X approximately is during at we statement of the high flows increase measure in this cash
million XXXX. continue on at of at to December work million working just XX, to September sheet, $XX.X million capital million equity Looking cash from $X.X XX, at compared the our approval fund at this XXXX. decreased Net development December XX, $XX,XXX $XX.X XXXX, FDA XX, to balance XXXX. required on XX, we decreased at $X.X XXXX XXXX September by while All million September achieve from XX, been December to just $XX to decreased has going and at Stockholders’ to Re-Tain. under
it role product of on in withhold Our the that mastitis of to milk polypeptide is disincentive development and that and A, that traditional require sick discarded objectives treating provides drugs in treatment a for sick the not be of subclinical saleable practice an economic mastitis benefit requirements and alternative still during this Nisin welfare to is intramammary industry, today’s common mastitis cows treat meat treated an period market the by antimicrobial, meat are subclinical dairy withheld and be play be cows all without labor removing a Re-Tain demonstrate the discard Because penalties. to productive milk offering our to allowing treatment milk. thereafter, antibiotics. to can today producing animal effective time
In This which addition and not including because sustainability safety food production in used enhances animals, important medicine. antibiotic welfare, to ongoing traditional concern. is animal which by is is in public Nisin, believed human human is food utilizing Re-Tain consumers, create to the in antibiotics, health improved overuse of resistance an
submission submission FDA. would section third So we be market Re-Tain. by the CMC technical is review six-month required This subject approval, to data of our to required all a the the are to make preparing which
We night. summary and known. financial look at business last the I please Mastitis industry the corporate subclinical but per on filed track remain November of our in believe a conclusion, quarter within to Also, and the we to have our current about very dairy presentation a the results. objectives, a $X With or our to excited economic quarter year. to on well section that this to that release review U.S. strategy disease as a good as first click provides Form report and it is you slide deck. XXXX, posted contact the I In take your are is XX-Q press questions. just website was Investors be not the Presentation way submission is I our happy presently see to the Corporate We treated. encourage during website exact for timing poised that of night, quarterly last that causes billion the and update copy. mastitis revolutionize will our said, harm make of on us A
lines, Chad open have Let’s please. up the
